Home Tools
Log in
Cart

CXCR

The CXCR signaling pathway family mainly comprises chemokines and chemokine receptors and CXCR consists of about 330 amino acids. The seven transmembrane regions divide the molecule into an extracellular free N-terminus, three extracellular loops, three intracellular loops, and several C-terminal portions.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T10635 Burixafor hydrobromide 1191450-19-7 98%
Burixafor hydrobromide
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in tre...
T78879 CXCR4-IN-2 98%
CXCR4-IN-2
CXCR4-IN-2 (compound A1), a potent bifunctional fluorinated small molecule, inhibits CXCR4 and exhibits anticancer properties by exerting cytotoxicity (IC 50: 60...
T79059 CXCR4-IN-1 2304750-48-7 98%
CXCR4-IN-1
CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic r...
T79070 Pentixafor 1341207-62-2 98%
Pentixafor
Pentixafor is a peptide that selectively targets the CXCR4 receptor and can be labeled with Gallium-68 (68Ga) for visualization using positron emission tomograph...
T80130 SDF-1α (human) 1268129-65-2 98%
SDF-1α (human)
SDF-1α (human) serves as a chemotactic agent for mononuclear cells through its interaction with the CXCR4 receptor, facilitating critical biological processes su...
T80216 DOTA-CXCR4-L 98%
DOTA-CXCR4-L
DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer [...
T80525 E70K 98%
E70K
E70K, a CXCL8 C-terminal peptide, features a lysine (K) substitution for glutamic acid (E) at position 70 and has demonstrated the ability to attenuate neutrophi...
T11140 E6130 1427058-33-0 98%
E6130
E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
T16933 SRT3190 1204707-73-2 98%
SRT3190
SRT3190 is an antagonist of CXCR2.
T12269L NUCC-390 dihydrochloride (1060524-97-1 free base) T12269L 98%
NUCC-390 dihydrochloride (1060524-97-1 free base)
NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
TN5227 (+/-)-Vestitol 56701-24-7 98%
(+/-)-Vestitol
Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to...
T16864 SCH 563705 473728-58-4 98%
SCH 563705
SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
T19386 ITIC 1664293-06-4 98%
ITIC
ITIC, a non-fullerene acceptor, demonstrates exceptional thermal stability and exhibits a glass-crystal transition at a significantly lower temperature than its ...
T6764 ATI-2341 1337878-62-2 98%
ATI-2341
ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to pro...
T19385 ITIC-4F 2097998-59-7 98%
ITIC-4F
ITIC-4F, an indacenodithienothiophene (IDTT)-based postfullerene electron acceptor, exhibits wide applicability in high-efficiency binary and ternary single-junc...
TP2141 Balixafortide TFA (1051366-32-5 free base) TP2141 98%
Balixafortide TFA (1051366-32-5 free base)
Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large pane...
T14665 Motixafortide 664334-36-5 98%
Motixafortide
Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
TP2141L Balixafortide 1051366-32-5 98%
Balixafortide
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and prog...
T0801 Tannic acid 1401-55-4 AR
Tannic acid
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
T1739 WZ811 55778-02-4 99.93%
WZ811
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
Burixafor hydrobromide
T10635
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in tre...
CXCR4-IN-2
T78879
CXCR4-IN-2 (compound A1), a potent bifunctional fluorinated small molecule, inhibits CXCR4 and exhibits anticancer properties by exerting cytotoxicity (IC 50: 60...
CXCR4-IN-1
T79059
CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic r...
Pentixafor
T79070
Pentixafor is a peptide that selectively targets the CXCR4 receptor and can be labeled with Gallium-68 (68Ga) for visualization using positron emission tomograph...
SDF-1α (human)
T80130
SDF-1α (human) serves as a chemotactic agent for mononuclear cells through its interaction with the CXCR4 receptor, facilitating critical biological processes su...
DOTA-CXCR4-L
T80216
DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer [...
E70K
T80525
E70K, a CXCL8 C-terminal peptide, features a lysine (K) substitution for glutamic acid (E) at position 70 and has demonstrated the ability to attenuate neutrophi...
E6130
T11140
E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
SRT3190
T16933
SRT3190 is an antagonist of CXCR2.
NUCC-390 dihydrochloride (1060524-97-1 free base)
T12269L
NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
(+/-)-Vestitol
TN5227
Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to...
SCH 563705
T16864
SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
ITIC
T19386
ITIC, a non-fullerene acceptor, demonstrates exceptional thermal stability and exhibits a glass-crystal transition at a significantly lower temperature than its ...
ATI-2341
T6764
ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to pro...
ITIC-4F
T19385
ITIC-4F, an indacenodithienothiophene (IDTT)-based postfullerene electron acceptor, exhibits wide applicability in high-efficiency binary and ternary single-junc...
Balixafortide TFA (1051366-32-5 free base)
TP2141
Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large pane...
Motixafortide
T14665
Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
Balixafortide
TP2141L
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and prog...
Tannic acid
T0801
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
WZ811
T1739
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
1 2 3 4
TargetMol